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Corrections
COLLOQUIUM PAPER. For the article ‘‘Synthetic zeolites and other
microporous oxide molecular sieves’’ by John D. Sherman, which
appeared in number 7, March 30, 1999, of Proc. Natl. Acad. Sci.
USA (96, 3471–3478), the author notes the following corrections:
(i) in Linear Paraffins for Biodegradable Detergents, OP ADS-34
should read UOP ADS-34; and (ii) in Impacts of Molecular Sieves
on Human Welfare, the phrase, ‘‘From these numbers,’’ should be
deleted.
Correction published online before print: Proc. Natl. Acad. Sci. USA, 10.1073y
pnas.110133597. Text and publication date are at www.pnas.orgycgiydoiy10.1073y
pnas.110133597
CELL BIOLOGY. For the article ‘‘Tyrosine phosphorylation of p62dok
by p210bcr-abl inhibits RasGAP activity’’ by Nobuhiro Kashige,
Nick Carpino, and Ryuji Kobayashi, which appeared in number
5, February 29, 2000, of Proc. Natl. Acad. Sci. USA (97, 2093–
2098), the authors note that the image in lane 12 of Fig. 6a was
mistakenly deleted in the printing process. The complete figure
and its legend are shown below.
Correction published online before print: Proc. Natl. Acad. Sci. USA, 10.1073y
pnas.110137997. Text and publication date are at www.pnas.orgycgiydoiy10.1073y
pnas.110137997
GENETICS. In the article ‘‘Toward Anopheles transformation:
Minos element activity in anopheline cells and embryos’’ by
Flaminia Catteruccia, Tony Nolan, Claudia Blass, Hans-Michael
Mu¨ller, Andrea Crisanti, Fotis C. Kafatos, and Thanasis G.
Loukeris, which appeared in number 5, February 29, 2000, of
Proc. Natl. Acad. Sci. USA (97, 2157–2162), the authors note that
three mistakes were introduced inadvertently in assembling Fig.
4. The revised Fig. 4 printed below includes the correct photo-
graph of E7 insertion at 21E, as well as the correct chromosomal
locations of E4 at 25D (2L) and E5 at 36B (3R).
Fig. 6. Peptide competition analysis indicates that Tyr-296 and Tyr-315 play
a critical role in the binding of p62dok to RasGAP. The ability of the diphos-
phopeptide to inhibit binding of Dok-1 to GAP suggests that the proper
positioning of pTyr-296 and pTyr-315 in tandem is critical for the interaction
of the two molecules. (a) Combinations of phosphopeptides corresponding to
the regions surrounding individual tyrosines in p62dok fail to inhibit the
binding of p62dok to RasGAP. However, a diphosphopeptide corresponding to
residues 293–322 is able to inhibit binding of Dok-1 to the GAP SH2-SH3-SH2
region. Binding analysis was conducted as described. Synthetic phosphopep-
tides used for this experiment were: 1, SPPALpYAEPLDS (pTyr-296); 2, SQD-
SLpYSDPLDS (pTyr-315); 3, PKEDPIpYDEPEGL (pTyr-362); 4, VPPQG LpYDL-
PREPK (pTyr-377); 5, RVKEEGpYELPYNPATDD (pTyr-398); 6, NPATDD pYAVP-
PPR (pTyr-409); and diphosphopeptide, PALpYAEPLDSLRIAPCPSQDS
LpYSDPLDST (pTyr-296 and pTyr-315). For control, unphosphorylated pep-
tides were used. Each phosphopeptide was added in concentration of 50 mM.
(b) Dose-dependent inhibition of p62dok binding to RasGAP by diphosphopep-
tide (Dok-1 aa 293–322). The diphosphopeptide was added in concentration
of 0.5, 5, or 50 mM. The unphosphorylated peptide was added in concentration
of 50 mM. (c) Dose-dependent inhibition of a truncated Dok-1 (the truncation
construct 316: residues 316–481) binding to RasGAP by diphosphopeptide.
The diphosphopeptide was added in concentration of 0.5, 5, or 50 mM. The
unphosphorylated peptide was added in concentration of 50 mM.
Fig. 4. (A) Sequences of the Minos insertion sites in the genome of Sua 5.1*
and Sua 4.0 cells. Chromosomal flanking sequences are represented with
capital letters in italics. Small lettering represents the sequences of the Minos
end. The expected TA dinucleotide of the insertion site is shown in bold. The
chromosomal divisions and subdivisions from which the flanking sequences
were derived are indicated with the chromosomal arm listed in parenthesis.
(B) Typical results of determining the location of origin of the rescued genomic
fragments by in situ localization to polytene chromosomes of the Suakoko
mosquito strain.
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PLANT BIOLOGY. For the article ‘‘Oryza sativa PSK gene encodes a
precursor of phytosulfokine-a, a sulfated peptide growth factor
found in plants’’ by Heping Yang, Yoshikatsu Matsubayashi,
Kenzo Nakamura, and Youji Sakagami, which appeared in
number 23, November 9, 1999, of Proc. Natl. Acad. Sci. USA (96,
13560–13565), the authors note the following correction. In line
18 of the first column on page 13565, ‘‘15 positions’’ should read
‘‘13 positions.’’
Correction published online before print: Proc. Natl. Acad. Sci. USA, 10.1073y
pnas.120161097. Text and publication date are at www.pnas.orgycgiydoiy10.1073y
pnas.120161097
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Tyrosine phosphorylation of p62dok by p210bcr-abl
inhibits RasGAP activity
Nobuhiro Kashige*†‡, Nick Carpino*†§¶, and Ryuji Kobayashi†i
†Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724; and §Program in Molecular and Cellular Biology, State University of
New York, Stony Brook, NY 11794-5215
Communicated by Michael H. Wigler, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, December 15, 1999 (received for review July 20, 1999)
The t(9;22) chromosomal translocation is found in almost all pa-
tients with chronic myelogenous leukemia. The resultant Bcr-Abl
fusion gene expresses a chimeric fusion protein p210bcr-abl with
increased tyrosine kinase activity. Hematopoietic progenitors iso-
lated from chronic myelogenous leukemia patients in the chronic
phase contain constitutively tyrosine-phosphorylated p62dok pro-
tein. p62dok associates with the Ras GTPase-activating protein
(RasGAP), but only when p62dok is tyrosine phosphorylated. Here
we have investigated the interaction between p62dok and RasGAP
and the consequences of p62dok tyrosine phosphorylation on the
activity of RasGAP. We have found that p62dok is directly tyrosine
phosphorylated by p210bcr-abl, and the sites of phosphorylation are
located in the C-terminal half of the p62dok molecule. We have
identified five tyrosine residues that are involved in in vitro RasGAP
binding and have found that tyrosine-phosphorylated p62dok in-
hibits RasGAP activity. Our results suggest that p210bcr-abl might
lead to the activation of the Ras signaling pathway by inhibiting a
key down-regulator of Ras signaling.
chronic myelogenous leukemia u Ras
Chronic myelogenous leukemia is a form of leukemia withdistinct clinical and pathological features (1). A well-
characterized chromosomal translocation within a single prim-
itive myeloid stem cells produces the chimeric bcr-abl gene,
which in turn leads to the generation of a 210 kDa Bcr-Abl
(p210bcr-abl) fusion protein. Relative to normal c-Abl, p210bcr-abl
has increased tyrosine kinase activity and can transform a variety
of fibroblastic and hematopoietic cell lines in culture (2, 3).
Although c-Abl, as a nonreceptor tyrosine kinase, functions in
both the nucleus and the cytoplasm, p210bcr-abl is exclusively
cytoplasmic. Both the elevated kinase activity and the subcel-
lular localization of the oncoprotein are considered essential
elements of its transforming abilities (4). Although the Ras
pathway has been reported to be activated in cells containing
p210bcr-abl (5, 6), the mechanism by which p210bcr-abl perturbs
normal hematopoiesis has not yet been established.
One of the major targets of p210bcr-abl in hematopoietic
progenitors is p62dok, the RasGAP-associated p62 protein (7).
p62dok (Dok-1) was first described as the major tyrosine-
phosphorylated protein present within cells transformed by
different activated tyrosine kinases (8). In addition, its state of
hypertyrosine phosphorylation has consistently correlated with
the transformed phenotype in cells expressing transforming
oncogenes such as v-fps, v-src, v-abl, Ras, and mos (8, 9).
Recently, the p62dok protein was isolated both from a p210bcr-abl
transformed myeloid cell line and a v-Abl-transformed B cell line
(10, 11). Cloning of the Dok-1 cDNA revealed the presence of
a pleckstrin homology (PH) domain in the N-terminal portion of
the protein molecule. PH domains are thought to mediate
protein interactions with cellular membranes, possibly by bind-
ing to polyphosphoinositides (12–14). Dok-1 also contains nu-
merous tyrosines in its C-terminal region that are potential
targets of cytoplasmic tyrosine kinases. If phosphorylated, these
tyrosines could serve as docking sites for proteins that contain
SH2 domains. These structural features are reminiscent of the
features found in such adaptor molecules as IRS-1 and IRS-2
(15), Gab1 (16–18), and Dos (19). Thus, the overall structure of
Dok-1 suggests that it might serve as a docking molecule for
different signaling molecules downstream of growth factor re-
ceptors.
Although at present the biological function of Dok-1 is
unclear, several lines of evidence suggest that it does indeed play
a role in distinct signal transduction networks, most likely as a
component of a signaling cascade initiated by receptor or
membrane-associated tyrosine kinases. The rapid tyrosine phos-
phorylation of a RasGAP-associated p62 in Rat-1 fibroblasts on
epidermal growth factor (EGF) stimulation and in Rat-2 fibro-
blasts on platelet-derived growth factor stimulation was reported
(8). Using a different system, Filvaroff et al. demonstrated the
tyrosine phosphorylation of a RasGAP-associated p62 in pri-
mary mouse keratinocytes as one of the initial events in calcium-
induced terminal differentiation (20). Other agents, such as
EGF, type b transforming growth factor, and phorbol ester, did
not induce tyrosine phosphorylation of the p62 within keratin-
ocytes, although they did result in the tyrosine phosphorylation
of the signaling molecules PLCg1 and PI3 kinase. In yet a
different biological context, application of the mitogen vascular
endothelial cell growth factor (VEGF) to bovine endothelial
cells resulted in tyrosine phosphorylation and RasGAP associ-
ation of a p62 protein, most likely Dok-1 (21). The VEGF-
stimulated tyrosine phosphorylation of p62 and the VEGF-
promoted proliferation of endothelial cells were both inhibited
by the tyrosine kinase inhibitor genistein. Thus, Dok-1 may
function in signaling pathways downstream of a variety of
receptors, in both transformed and nontransformed cells. How-
ever, the functional consequences of constitutive tyrosine phos-
phorylation of Dok-1 are still unclear.
Early studies revealed that when tyrosine phosphorylated,
Dok-1 forms an in vivo protein–protein complex with the Ras
regulatory protein p120 RasGAP (GAP). GAP interacts with
p21ras and stimulates the latter’s intrinsic GTPase activity (22).
Its catalytic activity is located in the C-terminal portion of the
molecule. In cells transformed by tyrosine kinases, GAP can be
found to be associated with both Dok-1 and a 190-kDa protein
known as p190 RhoGAP. Both proteins interact with the
N-terminal SH2-SH3-SH2 region of GAP (23). Unlike the
C-terminal region of GAP, the N-terminal region of GAP has no
known biochemical activity. However, the N-terminal noncata-
Abbreviations: PH, pleckstrin homology; Dok-1, p62dok; pTyr or pY, phosphotyrosine;
RasGAP, Ras GTPase-activating protein; GAP, p120 RasGAP.
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lytic region of GAP (but not full-length GAP) has been shown
to be active in several different biological assays, including
cytoskeletal reorganization, adhesion to extracellular matrix
(24), transcriptional activation (25), and inhibition of transfor-
mation induced by G protein-coupled receptors (26). The bio-
logical significance of the RasGAP-p62dok complex is unknown.
In this report, we analyze the interaction between GAP and
Dok-1, and we demonstrate that the activity of GAP toward Ras
is inhibited by the binding of tyrosine-phosphorylated Dok-1
to GAP.
Materials and Methods
Antibodies. A monoclonal antibody against the C-terminal tag
(RYIRS) was kindly provided by S. H. Lin (27) (Univ. of Texas,
M. D. Anderson Cancer Center, Houston). Anti-p62dok rabbit
polyclonal antibody was described previously (10), as was the use
of anti-pTyr monoclonal 4G10 (Upstate Biotechnology). Mono-
clonal anti-Bcr antibody and antihemagglutinin antibody
(12CA5) were from OSI (Uniondale, NY), and anti-GAP
(B4F8) was from Santa Cruz Biotechnology.
Cell Culture. Human 293 cells and monkey COS cells, obtained
from Cold Spring Harbor Laboratory Tissue Culture Facility,
were maintained in DMEM containing antibiotics 22 unitsyml
penicillin (GIBCOyBRL), 100 mgyml streptomycin (Sigma),
and 10% calf serum (GIBCOyBRL) at 37°C and 5% CO2. All
experiments utilized 293 cells between passages 1 and 20.
Mammalian expression constructs were electroporated into cells
at 200 V, 960 mF capacitance.
Immunoprecipitation, Immunoblotting, and RasGAP-Binding Assays.
Immunoprecipitation and blotting were as described (10). GST-
GAP proteins (constructs kindly provided by J. Schlessinger,
New York University, New York) were incubated with lysate for
30 min at 4°C, washed extensively with lysis buffer, and bound
proteins separated by SDSyPAGE.
In Vitro Kinase Reactions. Purified Dok-1 (250 ng), generated by
overexpression in Escherichia coli, was incubated with 100 units
Abl protein tyrosine kinase (NEB, Beverly, MA) in a buffer
recommended by the manufacturer. The reaction was allowed to
proceed at 30°C for the indicated time, after which it was stopped
by the addition of SDSyPAGE sample buffer. For the reaction
depicted in Fig. 1b, anti-Bcr antibodies were used to precipitate
proteins from lysates of Mo7 or Mo7yp210 cells (10). Protein
A-Sepharose beads (10 ml), to which the precipitated complexes
were bound, were incubated with in vitro-translated p62dok
according to instructions of the manufacturer. After a 30-min
incubation at 30°C, the kinase reaction was stopped by addition
of 500 ml precipitation buffer (10), and Dok-1 was precipitated
by addition of anti-p62dok antibodies or antiphosphotyrosine
antibody (4G10, Upstate Biotechnology).
Truncations. The PCR was used to create the tagged Dok-1
truncation products illustrated in Fig. 3a. Each construct was
sequenced and subcloned into the pMT2 mammalian expression
vector.
Site-Directed Mutagenesis. All Dok-1 Y3F point mutants were
generated by site-directed mutagenesis of double-stranded DNA
by using the QuickChange site-directed mutagenesis kit (Strat-
agene) according to manufacturer’s specifications. Mutagenesis
was confirmed by sequence analysis.
RasGAP Activity Assay. Immunoprecipitated RasGAP activity was
measured by analyzing the ratio of GTP and GDP bound to Ras
as previously described (28), with some modification. Recom-
binant human H-Ras (Calbiochem) was loaded with [a-32P]GTP
at 25°C for 10 min in 20 mM TriszHCl, pH 7.5, containing 5 mM
EDTA. RasGAP was produced by transient transfection in 293
cells and obtained by precipitation with anti-RasGAP (10 mg)
agarose conjugate (Santa Cruz Biotechnology). Enzyme activity
was assayed by incubating bound RasGAP with 60 ng
[a-32P]GTP-loaded Ras for 60 min or 90 min. In vitro-
phosphorylated Dok-1 (0, 0.05, 0.1, 0.5, and 1 mg) recombinant
wild-type or 1 mg of mutant Dok-1 was added to the reaction.
Reactions were terminated by adding ice-cold stop buffer con-
taining anti-H-Ras antibody agarose conjugate (Oncogene Sci-
ence), as described (28). After rocking this mixture for 45 min at
4°C, the resin was washed four times with 0.5 ml of 0.5%
(volyvol) Nonidet P-40 in stop buffer and then once with stop
buffer alone. The nucleotide was eluted off resin with 20 ml of
2 mM EDTAy2 mM DTTy0.2% SDSy0.5 mM GDPy0.5 mM
GTP by heating to 65°C for 5 min and then separated on
polyethyleneimine-cellulose TLC plate (J. T. Baker, Inc., Phil-
lipsburg, NJ) developed with 0.75 M KH2PO4 (pH 3.4). The
positions of GDP and GTP on the plates were visualized under
UV light by using standard GDP and GTP. Ras-bound GDP and
GTP were visualized by autoradiography and quantified by using
NIH IMAGE 1.62 to calculate the GTPyGDP ratio.
Results
Interaction Between p210bcr-abl, p62dok, and RasGAP. The presence of
tyrosine phosphorylation on p62dok in cells containing p210bcr-abl
Fig. 1. Tyrosine phosphorylation of p62dok by p210bcr-abl. (a) Time course, in
vitro abl kinase reaction utilizing purified recombinant p62dok as substrate.
p62dok is phosphorylated in a time-dependent manner by Abl. (b) In vitro
p210bcr-abl kinase reaction, utilizing in vitro-translated p62dok as substrate.
Monoclonal anti-bcr antibody was used to isolate p210bcr-abl. Immune complex
was incubated with in vitro-translated p62dok in the presence of g-32P-ATP.
Arrow indicates phosphorylated p62dok. (c) p210bcr-abl-dependent tyrosine
phosphorylation of p62dok, in vivo. Hemagglutinin-tagged Dok-1 and
p210bcr-abl were expressed in COS cells. Tyrosine phosphorylation of p62dok was
analyzed by precipitating the molecule from lysates derived from transfected
cells, resolving the immune complexes by SDSyPAGE and transfer to nitrocel-
lulose, and immunoblotting with anti-pTyr antibody (Top) or antihemagglu-
tinin antibody (Bottom). Arrow indicates p62dok.
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suggested that p62dok is a direct substrate of p210bcr-abl. None-
theless, it is also possible that p210bcr-abl might activate other
cytoplasmic tyrosine kinases that directly phosphorylate p62dok.
The ability of Dok-1 to be phosphorylated by p210bcr-abl was
tested in three separate assays. First, recombinant Dok-1 gen-
erated by overexpression in bacteria was tested as a substrate of
the isolated kinase domain of Abl. Fig. 1a illustrates that Dok-1
was phosphorylated in a time-dependent manner by the kinase
domain of Abl. This suggested that Dok-1 contains tyrosines
whose surrounding amino acid residues comprise a motif that
can be recognized by the Abl kinase. Because it is possible that
p210bcr-abl might interact with possible substrates differently than
the isolated Abl kinase domain, a second assay was used to test
the ability of Dok-1 to be phosphorylated by p210bcr-abl. Fig. 1b
illustrates that Dok-1, generated by in vitro translation of the
Dok-1 cDNA in a rabbit reticulocyte lysate system, could be
phosphorylated by p210bcr-abl isolated by immunoprecipitation
from lysates of Mo7yp210 cells with anti-Bcr antibody (lane 6).
That the incorporated phosphate was bonded to tyrosine was
indicated by the ability of antiphosphotyrosine antibodies to
precipitate Dok-1 (lane 8). Finally, an in vivo transfection assay
was used to test whether p210bcr-abl could phosphorylate Dok-1.
Dok-1 cDNA, cloned into a mammalian expression vector
downstream of sequences encoding the hemagglutinin Tag, was
cotransfected with the cDNA encoding p210bcr-abl into COS cells.
Fig. 1c illustrates that Dok-1 was tyrosine phosphorylated in a
p210bcr-abl -dependent fashion when overexpressed in COS cells.
These results indicate that p62dok can be phosphorylated by
p210bcr-abl, and that p62dok might be a substrate of p210bcr-abl
within primitive blasts of patients with chronic myelogenous
leukemia.
Numerous investigators working with a variety of transformed
cell lines have observed the tyrosine phosphorylation of p62dok
protein and its association with GAP (see for example refs. 8 and
29). The portion of the GAP molecule responsible for the
interaction with p62dok has been mapped to the N-terminal
region of GAP, comprising the SH2-SH3-SH2 domain (30).
Therefore, the need for p62dok to be tyrosine phosphorylated to
associate directly with GAP was tested. When recombinant
Dok-1 was tested for the ability to bind in vitro to the N-terminal
regions of GAP, only tyrosine-phosphorylated Dok-1 associated
in vitro with the N-terminal region of GAP (see Fig. 2a).
Similarly, when Dok-1 was overexpressed in 293 cells in the
presence or absence of p210bcr-abl it was observed that only
tyrosine-phosphorylated Dok-1 bound to GAP (see Fig. 2b).
This confirms the long-held suspicion that tyrosine phosphory-
lation of Dok-1 is necessary for the interaction between Dok-1
and GAP.
p62dok Truncations and RasGAP Binding. To assess the region of
p62dok, in particular the tyrosine(s), involved in the interaction
with GAP, a series of truncation mutants of Dok-1 was con-
structed. The structures of the Dok-1 mutants are illustrated in
Fig. 3a. Four different C-terminal truncations were constructed.
In each case, in the resulting Dok-1 protein a different tyrosine
and all amino acids C terminal to the selected tyrosine were
substituted with a C-terminal antigenic tag (27). The tyrosines at
which the different constructs were terminated were tyrosines
398, 362, 337, and 296. In addition to the C-terminal truncations,
two N-terminal truncations were constructed by replacing se-
quences encoding N-terminal amino acids with a starting ATG.
The resulting Dok-1 protein in one case lacked the PH domain
and in the other case lacked all amino acids N terminal to
Ala-294 (see Fig. 3a). When coexpressed with p210bcr-abl in 293
cells, each mutant Dok-1 protein became tyrosine phosphory-
lated, with the exception of the 295 Dok-1 mutant (see Fig. 3b).
Mutant Dok-1 proteins were also assessed for their ability to
bind in vitro to the SH2-SH3-SH2 region of GAP. As illustrated
in Fig. 3c, all mutant Dok-1 proteins with the exception of the
295 Dok-1 mutant were able to bind in vitro to the SH2-SH3-SH2
region of GAP. Thus, removal of all amino acid residues C
terminal to Tyr-337 or N terminal to Ala-294 did not prevent the
remaining portion of Dok-1 from binding in vitro to the SH2
region(s) of GAP. The mutant Dok-1 proteins were also assessed
for their ability to associate with GAP in vivo. Mutant Dok-1
proteins were expressed in 293 cells in the presence or absence
of p210bcr-abl. Then, antibodies directed against the C-terminal
antigenic tag were used to precipitate the mutant Dok-1 proteins
from extracts prepared from the transfected cells. As illustrated
in Fig. 3d, GAP coprecipitated with each mutant Dok-1 protein
in a p210bcr-abl-dependent fashion, with the exception of the 295
Dok-1 truncation mutant. These in vivo results complement the
results obtained in the in vitro binding assays; specifically, the in
vivo results point to the region between Dok-1 residues Ala-294
and Tyr-337 as involved in the association of Dok-1 with the SH2
domain(s) of GAP. Within the primary amino acid sequence of
this region of Dok-1 are two tyrosine residues spaced 18 amino
acids apart, Tyr-296 and Tyr-315. These tyrosines are implicated
as involved in the association of p62dok with GAP. However, our
data do not exclude the possibility that other tyrosines within the
C-terminal region of Dok-1 are tyrosine phosphorylated and
involved in GAP binding. In fact, Tyr-337, Tyr-362, and Tyr-398
of p62dok protein purified from p210bcr-abl expressing Mo7 cells
were found phosphorylated by mass spectrometry and protein
sequencing (data not shown).
Effect of p62dok Point Mutants on RasGAP Binding. The truncation
experiment identified Tyr-296 and Tyr-315 as least involved in
the association of Dok-1 to GAP. Indeed, it appeared likely that
Tyr-296 and Tyr-315, when phosphorylated, could interact with
the two SH2 domains of GAP, similar to the manner in which
Tyr-1087 and Tyr-1105 of p190 RhoGAP interacted with GAP
(31). To test the role of Tyr-296 and Tyr-315 in GAP binding, we
constructed a double Tyr3Phe point mutant Dok-1, in which
both tyrosines were altered to phenylalanine. The tagged double
Fig. 2. Interaction between p62dok and RasGAP. (a) Tagged p62dok was
expressed in E. coli, purified, and incubated in a kinase reaction in the
presence of Abl kinase (1) or buffer only (2). After the kinase reaction, p62dok
was incubated in an in vitro-binding reaction with glutathione-Sepharose
beads to which were bound GST(2), GST-GAP SH2-SH3-SH2 (232), GST-GAP
N-SH2 (N), or GST-GAP C-SH2 (C). Proteins bound to GST fusion proteins were
separated by SDSyPAGE, blotted to nitrocellulose, and detected by immuno-
blotting with antibodies to p62dok (a-p62dok) or phosphotyrosine (a-pTyr). (b)
Mammalian-expressed p62dok associates with RasGAP in a phosphorylation-
dependent manner. (Fig. 1b). C-terminally tagged Dok-1 cDNA was electro-
porated into 293 cell in the presence (1) or absence (2) of Bcr-Abl. After a 24-h
incubation, cells were lysed, and lysates were utilized in an in vitro- binding
reaction with glutathione-Sepharose beads to which were bound GST(2),
GST-GAP SH2-SH3-SH2 (232), GST-GAP N-SH2 (N), or GST-GAP C-SH2 (C).
Proteins bound to GST fusion proteins were separated by SDSyPAGE, blotted
to nitrocellulose, and detected by immunoblotting with antibodies to the
C-terminal tag (a-tag) or phosphotyrosine (a-pTyr).
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mutant Dok-1 protein was expressed in bacteria and phosphor-
ylated in vitro by Abl kinase. Then it was tested for its ability to
bind the GAP SH2-SH3-SH2 domain, as described. Interest-
ingly, this double-point mutant retained the ability to become
tyrosine phosphorylated and bind to GAP (Fig. 4, lane2). The
GAP-SH2 domains bind preferentially to phosphorylated ty-
rosine residues within the context of pYxxP (11, 32). There are
six tyrosine residues in p62dok that have proline in the 13
position: Tyr-296, Tyr-315, Tyr-362, Tyr-377, Tyr-398, and Tyr-
409. Therefore, additional mutant proteins in which combina-
tions of tyrosines were changed to phenylalanine were tested for
their ability to bind GAP. The Y296F, Y315F, Y362F triple point
mutant had reduced ability to bind GAP as compared with the
Y296, 315F double point mutant (see Fig. 4, lane 3). Further-
more, when we mutated Tyr-377 to phenylalanine in the context
of the Y296, 315, 362F triple mutant, the association of phos-
phorylated Dok-1 with GAP was significantly reduced (Fig. 4,
lane 4). However, even when either Tyr-398 or Tyr-409 was
additionally mutated to phenylalanine in the context of the
Y296, 315, 362, 377F quadruple mutant, we still observed in vitro
association of the mutant protein with GAP (Fig. 4, lanes 5 and
6). Finally, when we mutated five specific tyrosines to phenyl-
alanine (Y296, 315, 362, 398, 409F), we observed that Dok-1 was
no longer able to bind in vitro to the SH2-SH3-SH2 domain of
GAP (Fig. 4, lane 7). This suggests that these five tyrosines
contribute to the in vitro association of Dok-1 with GAP.
The Effect of Tyrosine-Phosphorylated p62dok on RasGAP Activity. To
test whether binding of Dok-1 to GAP had any effect on the
activity of GAP, we used an in vitro GAP activity assay (28). This
assay measures the ability of GAP to increase the intrinsic
GTPase rate of GTP-Ras. We analyzed the in vitro activity of
GAP in the presence of tyrosine-phosphorylated wild-type
Dok-1 or in the presence of a five Tyr3Phe point mutant unable
to associate with GAP (see Fig. 4, lane 7). The assays were
carried out with Dok-1 proteins phosphorylated both in vivo and
in vitro. In vivo tyrosine-phosphorylated wild-type or mutant
Dok-1 (Fig. 4, lane 7) was prepared by immunoprecipitation of
Fig. 3. Removal of N- and C-terminal residues from p62dok does not prevent
its in vitro and in vivo association with RasGAP. (a) Schematic diagram of
p62dok truncations. Four C-terminal Dok-1 truncations were constructed. In
each case, a different tyrosine (residues 398, 362, 337, and 296) and all amino
acids C terminal to the selected tyrosine were replaced with a C-terminal
antigenic tag (RYIRS, black oval). Additionally, two N-terminal truncations
were constructed, lacking either the PH domain (2PH) or the entire N-terminal
region (2N). The vertical bars mark the location of the tyrosines within p62dok.
The PH domain is indicated (PH). (b) Tyrosine phosphorylation of p62dok
truncations. The indicated Dok-1 truncations and p210bcr-abl were expressed in
293 cells. Antibody directed against the C-terminal tag was used to precipitate
Dok-1 proteins. Immune complexes were analyzed by immunoblotting by
using antibodies against the C-terminal tag (TAG, Left) or phosphotyrosine
(pTyr, Right). Bands derived from IgG are indicated as IgG-H and IgG-L. The
only Dok-1 mutant to lack detectable tyrosine phosphorylation in the pres-
ence of p210bcr-abl was that which lacked all 10 C-terminal tyrosines (295). (c)
Removal of N-terminal and C-terminal residues from p62dok does not prevent
its in vitro association with RasGAP. The indicated Dok-1 truncations and
Bcr-Abl were expressed in 293 cells. Cell lysates were prepared and utilized in
an in vitro binding reaction to glutathione-Sepharose beads to which were
bound GST (2) or GST-GAP SH2-SH3-SH2 region. Bound proteins were sepa-
rated by SDSyPAGE, blotted to nitrocellulose, and detected by immunoblot-
ting with antibodies to the C-terminal tag (Left) or to p62dok (Right). The only
Dok-1 mutant unable to associate with GAP was that which lacked all 10
C-terminal tyrosines (295). (d) Removal of N-terminal and C-terminal residues
from p62dok does not prevent its in vivo association with RasGAP. Dok-1
truncations and p210bcr-abl were expressed in 293 cells as described above.
Lysates were prepared, and antibodies to the C-terminal tag were used to
precipitate Dok-1 proteins. The resulting immunoblot was probed with anti-
body directed against GAP (Top) or against phosphotyrosine (Bottom).
Fig. 4. Only when five specific tyrosines are mutated to phenylalanine is the
binding of p62dok to the RasGAP SH2-SH3-SH2 region abrogated. The indi-
cated tyrosine-to-phenylalanine mutants of Dok-1 were coexpressed in 293
cells with p210bcr-abl. Cell lysates were prepared and divided into two. Mutant
Dok-1 was precipitated from one portion and detected after SDSyPAGE by
antibodies to Dok-1 (Top) or antibody to phosphotyrosine (Middle), whereas
the other portion was utilized in an in vitro binding reaction to GST-GAP
SH2-SH3-SH2 (Bottom). Nonmutated tyrosine residue is indicated (1).
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Dok-1 from lysates of 293 cells coexpressing p62dok and
p210bcr-abl. We observed a significant (approximately 35%)
diminution of GAP activity when the assay was conducted in the
presence of wild-type tyrosine-phosphorylated Dok-1 (see Fig.
5a, lane 5). In contrast, we observed no diminution of GAP
activity when the assay was conducted in the presence of
nontyrosine-phosphorylated Dok-1 (Fig. 5a, lane 6) or in the
presence of a five Tyr3Phe point mutant Dok-1 unable to bind
GAP (see Fig. 5a, lanes 7 and 8). In vitro tyrosine-
phosphorylated wild-type or mutant Dok-1 was prepared by
phosphorylation of bacterially expressed Dok-1 by c-Abl kinase.
Again, we observed a significant diminution of GAP activity
when the assay was conducted in the presence of phosphorylated
wild-type Dok-1 as compared with GAP activity in the presence
of nontyrosine-phosphorylated wild-type Dok-1 or a five
Tyr3Phe point mutant Dok-1 unable to bind GAP (compare
with Fig. 5b Top and Bottom). These results indicate that the
association of tyrosine-phosphorylated Dok-1 with GAP can
inhibit the GTPase-activating activity of GAP.
Peptide Competition Analysis. We synthesized tyrosine-phospho-
rylated peptides (15 mer) corresponding to the region surround-
ing each of tyrosines in YxxP motif (see Fig. 6 Legend). Then we
attempted to inhibit the interaction between Dok-1 and the
SH2-SH3-SH2 domain of GAP by including the peptides in the
in vitro binding reaction described in Fig. 2. Interestingly, any
mixture of the singly tyrosine-phosphorylated peptides contain-
ing pYxxP motif, including the five GAP-binding tyrosines (Fig.
4, lane 7), failed to inhibit in vitro association of Dok-1 with the
SH2-SH3-SH2 domain of GAP (Fig. 6a, lanes 2–11, and data not
shown).
Recently, Hu and Settleman demonstrated that the critical
determinants of p190 RhoGAP mediating the association of
p190 with GAP are two tyrosines spaced 17 residues apart,
Tyr-1087 and Tyr-1105 (31). These tyrosines lie within the motif
YxxPxD, and each appears to bind simultaneously to the two
SH2 domains of GAP. There are two tyrosines of p62dok that lie
within the motif YxxPxD, Tyr-296, and Tyr-315. Similar to the
tyrosines within p190 RhoGAP, they are spaced 18 residues
apart. We synthesized a diphosphopeptide of 30 amino acids
corresponding to the residues surrounding Tyr-296 and Tyr-315
and attempted to inhibit the in vitro interaction between p62dok
and RasGAP by including the diphosphopeptide in the binding
reaction. The diphosphopeptide completely inhibited the in vitro
association of wild-type p62dok to RasGAP [Fig. 6 a (lane 12) and
b). Furthermore, the diphosphopeptide was able to inhibit the
GAP association of a truncated Dok-1 that lacked all amino
acids N terminal to Tyr-315 (see Fig. 6c). These results suggest
that although five tyrosines within the C-terminal region of
Fig. 5. Tyrosine-phosphorylated p62dok inhibits RasGAP activity. (a) In vivo
phosphorylated wild-type Dok-1 by p210bcr-abl inhibits GAP activity toward
Ras. However, a mutant Dok-1 that does not bind to GAP has no effect on GAP
activity. (b) In vitro-phosphorylated Dok-1 by Abl tyrosine kinase also inhibits
GAP activity, whereas a mutant Dok-1 has no effect. v, vector only; W,
wild-type p62dok; M, five-tyrosine mutant p62dok.
Fig. 6. Peptide competition analysis indicates that Tyr-296 and Tyr-315 play
a critical role in the binding of p62dok to RasGAP. The ability of the diphos-
phopeptide to inhibit binding of Dok-1 to GAP suggests that the proper
positioning of pTyr-296 and pTyr-315 in tandem is critical for the interaction
of the two molecules. (a) Combinations of phosphopeptides corresponding to
the regions surrounding individual tyrosines in p62dok fail to inhibit the
binding of p62dok to RasGAP. However, a diphosphopeptide corresponding to
residues 293–322 is able to inhibit binding of Dok-1 to the GAP SH2-SH3-SH2
region. Binding analysis was conducted as described. Synthetic phosphopep-
tides used for this experiment were: 1, SPPALpYAEPLDS (pTyr-296); 2, SQD-
SLpYSDPLDS (pTyr-315); 3, PKEDPIpYDEPEGL (pTyr-362); 4, VPPQG LpYDL-
PREPK (pTyr-377); 5, RVKEEGpYELPYNPATDD (pTyr-398); 6, NPATDD pYAVP-
PPR (pTyr-409); and diphosphopeptide, PALpYAEPLDSLRIAPCPSQDS
LpYSDPLDST (pTyr-296 and pTyr-315). For control, unphosphorylated pep-
tides were used. Each phosphopeptide was added in concentration of 50 mM.
(b) Dose-dependent inhibition of p62dok binding to RasGAP by diphosphopep-
tide (Dok-1 aa 293–322). The diphosphopeptide was added in concentration
of 0.5, 5, or 50 mM. The unphosphorylated peptide was added in concentration
of 50 mM. (c) Dose-dependent inhibition of a truncated Dok-1 (the truncation
construct 316: residues 316–481) binding to RasGAP by diphosphopeptide.
The diphosphopeptide was added in concentration of 0.5, 5, or 50 mM. The
unphosphorylated peptide was added in concentration of 50 mM.
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Dok-1 can contribute to GAP binding, Tyr-296 and Tyr-315
double mutant may play the predominant role. Because a
mixture of five singly phosphorylated peptides (including Tyr-
296 and Tyr-315) was not able to completely inhibit the GAP
binding (see Fig. 6a, lane 10), our results also suggest that a
configuration that positions the two YxxPxD motifs (Tyr-296 and
Tyr-315) is critical for the interaction of p62dok with RasGAP.
Discussion
The GAP-Associated 62-kDa protein, p62dok, was first described
as the major tyrosine-phosphorylated protein present within
cells transformed by different activated tyrosine kinases. Among
the cell types in which Dok-1 has been shown to be constitutively
tyrosine phosphorylated are primary hematopoietic progenitors
isolated from chronic myelogenous patients in the chronic phase
(7). These cells contain the p210bcr-abl oncogene, an aberrant
form of the Abl tyrosine kinase produced as a result of the t(9;22)
chromosomal translocation (the Philadelphia chromosome). In
this study, we have presented evidence that p62dok is a direct
target of the p210bcr-abl kinase. In addition, we have demon-
strated that tyrosine phosphorylation of Dok-1 is necessary for
its association with the N-terminal SH2-SH3-SH2 region of p120
RasGAP. Our data suggest that five phosphotyrosines, pTyr-
296, pTyr-315, pTyr-362, pTyr-398, and pTyr-409, of p62dok
contribute to GAP association. Because tyrosine-phosphory-
lated p62dok isolated from cells expressing p210bcr-abl appears as
a doublet in one-dimensional gel electrophoresis and as three to
four spots in two-dimensional gel electrophoresis (10), multiple
species of p62dok clearly exist in cells. Although Tyr-296 and
Tyr-315 appear to play a critical role in in vitro GAP association,
at present we do not know whether they play a similar role in vivo.
We also do not know either the stoichiometry of in vivo
phosphorylation or the order in which each tyrosine becomes
phosphorylated in vivo. Because there are only two SH2 domains
in GAP, it is possible that when two phosphotyrosines of p62dok
are binding to GAP, other phosphotyrosines are available to
interact with other SH2 domain-containing proteins. We antic-
ipate that the intracellular interaction of p210bcr-abl, p62dok, and
GAP is complex. Further investigation is necessary to study
tyrosine phosphorylation of p62dok and its interacting proteins.
Finally and most importantly, we have demonstrated that
Dok-1 binding to RasGAP negatively affects GAP’s activity in
vitro toward the GTPase activity of Ras. Previously, Skorski et
al. reported (33) that p210bcr-abl negatively regulate the GT-
Pase-promoting activity of GAP in chronic myelogenous leu-
kemia cells. Our results are in agreement with their report.
Pendergast et al. reported that Bcr-Abl forms a complex with
Grb2 in vivo, and this interaction is required for Bcr-Abl-
induced Ras activation (5). It is possible that there are several
mechanisms for Bcr-Abl to activate Ras, including the follow-
ing two scenarios: (i) by modulating the association and
activity of the Grb2ySos exchange factor complex; and (ii) by
phosphorylating p62dok, which in turn down-regulates Ras-
GAP activity.
It is currently unknown whether phosphorylation of p62dok
affects the MAP kinase-signaling pathway, or whether p62dok
plays a role in a signaling pathway parallel to a MAP kinase
pathway. Both GAP and Dok-1 are predominantly cytosolic,
although a portion of the GAPyDok-1 complex translocates to
the inner surface of the plasma membrane on growth factor
stimulation (34).
Although at present the biological function of p62dok is not
known, our data suggest that one effect of p62dok constitutive
tyrosine phosphorylation is to disrupt the activity of a key
down-regulator of the Ras signaling pathway. Thus, constitutive
p62dok tyrosine phosphorylation might directly contribute to the
phenotypic and behavioral differences observed in chronic
myelogenous leukemia hematopoietic progenitors (35).
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